Back to medical news
MedPage Today
Chinese Drug Shows Benefit in HER2-Low Breast Cancer
October 23, 2026
Original source summary
(MedPage Today) -- An investigational antibody-drug conjugate (ADC) significantly reduced the risk of disease progression or death in patients with HER2-low metastatic breast cancer, a Chinese phase III trial showed. The drug, trastuzumab rezetecan...
Verbatim from MedPage Today's own feed — "Chinese Drug Shows Benefit in HER2-Low Breast Cancer"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news